Citations

Showing 10 of 107885 citations.

Positron-Emission Tomography Imaging of the Angiotensin II Subtype 1 Receptor in Swine Renal Artery Stenosis
Xia, Jinsong, Seckin, Esen, Xiang, Yan, Vranešić, Melin, Mathews, William B. , Bluemke, David A. , Lerman, Lilach O. , Szabó, Zsolt , Xiang, Yan, Hong, Kelvin K. , Bluemke, David A

Mayo Clinic

Hypertension | January 2, 2008 | Volume: 51 | Issue: 2 | Pages: 466-473

10.1161/hypertensionaha.107.102715 | PMID 18172054 Get It

The angiotensin II subtype 1 receptor (AT 1 R) has been linked to the development and progression of renovascular hypertension. In this study we applied a pig model of renovascular hypertension to investigate the AT 1 R in vivo with positron-emission tomography (PET) and in vitro with quantitative autoradiography. AT 1 R PET measurements were performed with the radioligand [ 11 C]KR31173 in 11 control pigs and in 13 pigs with hemodynamically significant renal artery stenosis; 4 were treated with lisinopril for 2 weeks before PET imaging. The radioligand impulse response function was calculated by deconvolution analysis of the renal time-activity curves. Radioligand binding was quantified by the 80-minute retention of the impulse response function. Median values and interquartile ranges were used to illustrate group statistics. Radioligand retention was significantly increased ( P =0.044) in hypoperfused kidneys of untreated (0.225; range: 0.150 to 0.373) and lisinopril-treated (0.237; range:0.224 to 0.272) animals compared with controls (0.142; range:0.096 to 0.156). Increased binding of [ 11 C]KR31173 documented by PET in vivo was confirmed by in vitro autoradiography. Both in vivo and in vitro binding measurements showed that the effect of renal artery stenosis on the AT 1 R was not abolished by lisinopril treatment. These studies provide insight into kidney biology as the first in vivo/in vitro experimental evidence about AT 1 R regulation in response to reduced perfusion of the kidney. The findings support the concept of introducing AT 1 R PET as a diagnostic biomarker of renovascular disease.
Immunohistochemical expression of nestin in adenohypophysial vessels during development of pituitary infarction
Salehi, Fateme , Kovács, Kálmán, Cusimano, Michael D. , Horváth, Éva , Bell, C. David , Rotondo, Fabio , Scheithauer, Bernd W.

Mayo Clinic

Journal of Neurosurgery | January 2, 2008 | Volume: 108 | Issue: 1 | Pages: 118-123

10.3171/jns/2008/108/01/0118 | PMID 18173320 Get It

Object The aim of this work was to investigate the immunohistochemical expression of nestin, a member of the intermediate filament family, in adenohypophysial vasculature during development and progression of pituitary infarction. Methods Forty-five nontumorous adenohypophyses and 34 pituitary adenomas of various types, all exhibiting acute or healing infarcts, were examined immunohistochemically using the streptavidin-biotin-peroxidase complex method. Results In both adenohypophyses and pituitary adenomas without infarction, nestin was expressed in only a few capillaries and endothelial cells. In acute infarcts without a vascular response, no nestin was demonstrable within necrotic capillaries (50 cases). In organizing infarcts, newly formed vessels spreading into necrotic zones showed nestin expression in all capillaries and practically every endothelial cell (25 cases). In the hypocellular, fibrotic scar phase, only a few vessels (4) were apparent, and immunoreactivity was focal and mild. Conclusions Nestin is strongly expressed in newly formed capillaries and is downregulated when infarcts transform to fibrous tissue. Nestin expression may provide valuable insight into the process of pituitary angiogenesis.
Neurology
Noseworthy, John H.

Mayo Clinic

Neurology | December 31, 2007 | Volume: 70 | Issue: 1 | Pages: 2-4

10.1212/01.wnl.0000299188.85136.56 Get It

A 23-year-old man with seizures and visual deficit
Boustany, Rose-Mary N., Parisi, Joseph E., Boustany, Rose‐Mary , Britton, Jeffrey W. , Keegan, B. Mark

Mayo Clinic

Neurology | December 31, 2007 | Volume: 70 | Issue: 1 | Pages: 73-78

10.1212/01.wnl.0000298372.36118.1f | PMID 18166709 Get It

New Genes, New Dilemmas: FTLD Genetics and Its Implications for Families
Adamson, Jennifer, Karydas, Anna, Hutton, Mike, Goldman, Jill , Miller, Bruce L.

Mayo Clinic

American Journal of Alzheimer's Disease & Other Dementias® | December 31, 2007 | Volume: 22 | Issue: 6 | Pages: 507-515

10.1177/1533317507306662 | PMID 18166610 Get It

After Alzheimer's disease, frontotemporal lobar degeneration (FTLD) is the second leading cause of dementia in persons less than 65 years of age. Up to 40% of FTLD cases have a positive family history. Research on these families has led to the discovery of four disease-causing genes: microtubule-associated protein tau ( MAPT), progranulin ( PGRN), valosin-containing protein ( VCP), and charged multivesicular body protein 2B ( CHMP2B). MAPT and PGRN are responsible for the largest number of familial cases. Each of these genes differs by disease mechanism. Moreover mutations in both genes are associated with significant interfamilial and intrafamilial phenotypic variation. Genetic counseling needs to address the differences between the PGRN and MAPT mutations as well as the variation in clinical symptoms. The aims of this article are to describe the genetics of the FTLD spectrum and aid in the genetic counseling of individuals who may carry genetic mutations.
Medical Management of Frontotemporal Dementia
Caselli, Richard J. , Yaari, R.

Mayo Clinic

American Journal of Alzheimer's Disease & Other Dementias® | December 31, 2007 | Volume: 22 | Issue: 6 | Pages: 489-498

10.1177/1533317507306654 | PMID 18166608 Get It

There are no Food and Drug Administration (FDA)-approved medications for the medical management of frontotemporal dementia and its related disorders, so all management recommendations are necessarily off-label and borrowed from experience with Alzheimer's disease, psychiatric disease, and related medical illnesses. Six areas of pharmacotherapeutic consideration are prevention (primary and secondary), intellectual decline, behavioral disorders (such as depression, anxiety, and psychosis), sleep disorders, frequently associated disorders (including motor neuron disease), and abrupt decline. In addition to pharmacotherapy, important lifestyle issues confronting the clinician include driving cessation, securing any weapons maintained at home, assisted living, and caregiver burnout.
Acridine-Based Agents with Topoisomerase II Activity Inhibit Pancreatic Cancer Cell Proliferation and Induce Apoptosis
Goodell, John R. , Ougolkov, Andrei V., Hiasa, Hiroshi , Remmel, Rory P. , Billadeau, Daniel D. , Ferguson, David M. , Ugolkov, Andrey , Kaur, Harneet

Mayo Clinic

Journal of Medicinal Chemistry | December 29, 2007 | Volume: 51 | Issue: 2 | Pages: 179-182

10.1021/jm701228e | PMID 18163538 Get It

Randomized Trials in Oncology Stopped Early for Benefit
Djulbegović, Benjamin , Montori, Víctor M. , Wilcox, Ryan A. , Guyatt, Gordon , Montori, Victor M

Mayo Clinic

Journal of Clinical Oncology | December 28, 2007 | Volume: 26 | Issue: 1 | Pages: 18-19

10.1200/jco.2007.13.6259 | PMID 18165635 Get It

Does Marital Status Impact Survival and Quality of Life in Patients with Non-Small Cell Lung Cancer? Observations from the Mayo Clinic Lung Cancer Cohort
Jatoi, Aminah , Novotny, Paul J. , Cassivi, Stephen D. , Clark, Matthew M. , Midthun, David E. , Sloan, Jeff A. , Patten, Christi A. , Yang, Ping

Mayo Clinic

The Oncologist | December 28, 2007 | Volume: 12 | Issue: 12 | Pages: 1456-1463

10.1634/theoncologist.12-12-1456 | PMID 18165623 Get It

Abstract Purpose. Previous studies have found that marriage is associated with longer survival and better quality of life among lung cancer patients. The present study used the Mayo Clinic Lung Cancer Cohort to re-examine this issue. Methods. In total, 5,898 non-small cell lung cancer (NSCLC) patients, who had available information on marital status and who had been enrolled in the Mayo Clinic Lung Cancer Cohort (MCLCC), were the focus of this study. Patients had extensive baseline and follow-up data on cancer stage, cancer treatment, and prognostic factors. All patients had been followed within the MCLCC with at least annual confirmation of vital status and patient-reported quality of life (the Lung Cancer Symptom Scale and the Linear Analogue Scales of Assessment). Results. The numbers of patients who were married, single, divorced, and widowed at the time of cancer diagnosis were 4,457 (76%), 265 (4%), 440 (7%), and 736 (12%), respectively. No statistically significant difference in survival was observed among these four groups, even after adjusting for a variety of prognostic factors, such as age, gender, and tumor stage. However, exploratory analyses suggested that widowed and divorced patients received less aggressive cancer therapy, and certain patient subgroups, such as stage IA widowed patients, had a shorter survival. Divorced patients reported greater financial concerns, and married and widowed patients reported greater spirituality and better social support. Conclusion. This study did not observe differences in survival or quality of life based on marital status at the time of diagnosis of NSCLC, but subgroup analyses appear to suggest findings worthy of further exploration.